BD (Becton, Dickinson and Company) has announced a $110m investment to expand its production of prefillable syringes in the US. The company aims to strengthen the pharmaceutical supply chain and accelerate the delivery of biologic and glucagon-like peptide-1 (GLP-1) drugs. BD will introduce Neopak Glass Prefillable Syringe manufacturing at its facility in Columbus, Nebraska. Available in 1ml and 2.25ml formats, the platform is designed to support various formulation needs, including high viscosity and ...